

541, 216

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/061433 A1

- (51) International Patent Classification⁷: G01N 21/27, 25/08, C07B 63/00, A61K 31/415
- (71) Applicant (for all designated States except US): TRANSFORM PHARMACEUTICALS, INC. [US/US]; 29 Hartwell Avenue, Lexington, MA 02421 (US).
- (21) International Application Number: PCT/US2003/041273
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): TAWA, Mark [US/US]; 111 Kenrick Street, Brighton, MA 02135 (US). REMENAR, Julius [US/US]; 9 Eaton Road, Framingham, MA 01701 (US). PETERSON, Matthew [US/US]; 60 Linda Avenue, Framingham, MA 01701 (US). ALMARS-SON, Orn [IS/US]; 22 Farmington Drive, Shrewsbury, MA 01545 (US). GUZMAN, Hector [US/US]; 11 Bradford Street, Apartment 1, Boston, MA 02118 (US). CHEN, Hongming [CN/US]; 8 Sawmill Road, Acton, MA 01720 (US). OLIVEIRA, Mark [US/US]; 290 Grove Street Apt. 10, Auburndale, MA 02466 (US).
- (22) International Filing Date: 24 December 2003 (24.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
- | | | |
|----------------|--------------------------------|----|
| 60/437,516 | 30 December 2002 (30.12.2002) | US |
| 60/441,335 | 21 January 2003 (21.01.2003) | US |
| 60/451,213 | 28 February 2003 (28.02.2003) | US |
| 60/456,027 | 18 March 2003 (18.03.2003) | US |
| 60/456,608 | 21 March 2003 (21.03.2003) | US |
| 60/459,501 | 1 April 2003 (01.04.2003) | US |
| 10/601,092 | 20 June 2003 (20.06.2003) | US |
| PCT/US03/19574 | 20 June 2003 (20.06.2003) | US |
| 60/486,713 | 11 July 2003 (11.07.2003) | US |
| 60/487,064 | 11 July 2003 (11.07.2003) | US |
| PCT/US03/27772 | | |
| | 4 September 2003 (04.09.2003) | US |
| 10/660,202 | 11 September 2003 (11.09.2003) | US |
| PCT/US03/28982 | | |
| | 16 September 2003 (16.09.2003) | US |
- (74) Agents: EISENSCHENK, Frank, C. et al.; Saliwanchik, Lloyd & Saliwanchik, 2421 N.W. 41st Street, Suite A-1, Gainesville, FL 32606-6669 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
- | | |
|----------|--------------------------------|
| US | 10/601,092 (CIP) |
| Filed on | 20 June 2003 (20.06.2003) |
| US | PCT/US03/19574 (CIP) |
| Filed on | 20 June 2003 (20.06.2003) |
| US | PCT/US03/27772 (CIP) |
| Filed on | 4 September 2003 (04.09.2003) |
| US | 10/378,956 (CIP) |
| Filed on | 3 March 2003 (03.03.2003) |
| US | 10/660,202 (CIP) |
| Filed on | 11 September 2003 (11.09.2003) |
| US | 10/637,829 (CIP) |
| Filed on | 8 August 2003 (08.08.2003) |
| US | 10/449,307 (CIP) |
| Filed on | 30 May 2003 (30.05.2003) |
| US | PCT/US03/28982 (CIP) |
| Filed on | 16 September 2003 (16.09.2003) |
- (54) Title: PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION
- (57) Abstract: The invention relates to methods of screening mixtures containing a pharmaceutical compound and an excipient to identify properties of the pharmaceutical compound/excipient combination that retard solid-state nucleation. The invention further relates to increasing the solubility, dissolution and bioavailability of a drug with low solubility in gastric fluids conditions by combining the drug with a precipitation retardant and an optional enhancer.

WO 2004/061433 A1